

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Gryaznov Sergei	2. Date of Event Requiring Statement (Month/Day/Year) 07/27/2022	3. Issuer Name and Ticker or Trading Symbol MAIA Biotechnology, Inc. [MAIA]
(Last) (First) (Middle) 444 WEST LAKE STREET, SUITE 1700		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Scientific Officer
(Street) CHICAGO, IL 60606		5. If Amendment, Date Original Filed(Month/Day/Year)
(City) (State) (Zip)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	21,511 <u>(1)</u>	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options	<u>(2)</u>	11/30/2029	Common Stock	200,000	\$ 1.8	D	
Stock Options	<u>(3)</u>	11/30/2029	Common Stock	58,000	\$ 1.8	D	
Stock Options	<u>(4)</u>	04/01/2030	Common Stock	54,000	\$ 1.8	D	
Stock Options	<u>(5)</u>	11/02/2030	Common Stock	236,493	\$ 1.8	D	
Stock Options	<u>(6)</u>	12/31/2030	Common Stock	23,695	\$ 1.8	D	
Stock Options	<u>(7)</u>	04/15/2031	Common Stock	164,662	\$ 1.83	D	
Stock Options	<u>(8)</u>	04/15/2031	Common Stock	78,413	\$ 1.83	D	
Stock Options	<u>(9)</u>	03/31/2031	Common Stock	23,078	\$ 1.83	D	
Stock Options	<u>(10)</u>	04/15/2031	Common Stock	50,000	\$ 1.83	D	
Stock Options	<u>(11)</u>	06/30/2031	Common Stock	7,529	\$ 1.83	D	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Gryaznov Sergei 444 WEST LAKE STREET, SUITE 1700			Chief Scientific Officer	

## Signatures

/s/ Sergei M. Gryaznov

07/27/2022

Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Mr. Gryaznov beneficially owns 21,511 shares of common stock.
- (2) Represents an option to purchase shares of Common Stock granted pursuant to the 2018 Stock Option Plan. These options fully vested on December 1, 2019.
- (3) Represents an option to purchase shares of Common Stock granted pursuant to the 2018 Stock Option Plan. These options vested in four equal monthly installments on December 1, 2019.
- (4) Represents an option to purchase shares of Common Stock granted pursuant to the 2018 Stock Option Plan. 6,055 of these options vested on April 30, 2020 and 47,945 of these options vested on January 1, 2021.
- (5) Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on November 3, 2020.
- (6) Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options vested in 90 equal daily instalments beginning on January 1, 2021.
- (7) Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on May 20, 2021.
- (8) Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on May 20, 2021.
- (9) Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options vested in 90 equal daily instalments beginning on April 2, 2021.
- (10) Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options vested in 36 equal monthly instalments beginning on January 1, 2021.
- (11) Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on July 1, 2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.